Free Trial

Bicara Therapeutics (NASDAQ:BCAX) Insider David Raben Sells 22,000 Shares

Bicara Therapeutics logo with Medical background

Key Points

  • David Raben, an insider at Bicara Therapeutics, sold 22,000 shares at an average price of $18.45, totaling $405,900, which represents a 38.26% decrease in his ownership.
  • Bicara Therapeutics' stock is currently trading at $17.78 with a market capitalization of $971 million and a PE ratio of -5.61, indicating potential challenges in profitability.
  • Recent analysis shows that the company's stock has received a mix of ratings, with one "Strong Buy," five "Buy," and one "Sell," reflecting varied investor sentiment.
  • Five stocks to consider instead of Bicara Therapeutics.

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) insider David Raben sold 22,000 shares of the company's stock in a transaction dated Thursday, October 9th. The stock was sold at an average price of $18.45, for a total value of $405,900.00. Following the completion of the transaction, the insider owned 35,497 shares of the company's stock, valued at $654,919.65. The trade was a 38.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Bicara Therapeutics Stock Performance

BCAX stock traded down $0.48 during trading on Friday, hitting $17.78. 386,878 shares of the company traded hands, compared to its average volume of 577,732. The firm has a market capitalization of $971.00 million and a PE ratio of -5.61. Bicara Therapeutics Inc. has a 1 year low of $7.80 and a 1 year high of $28.09. The company has a 50-day moving average of $12.36 and a 200-day moving average of $11.83.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.04. Sell-side analysts expect that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Nuveen LLC purchased a new position in shares of Bicara Therapeutics in the 1st quarter valued at approximately $326,000. New York State Common Retirement Fund bought a new position in Bicara Therapeutics during the 1st quarter valued at approximately $52,000. GAMMA Investing LLC increased its position in Bicara Therapeutics by 13,040.7% during the 1st quarter. GAMMA Investing LLC now owns 7,753 shares of the company's stock valued at $101,000 after buying an additional 7,694 shares in the last quarter. CWM LLC bought a new position in Bicara Therapeutics during the 1st quarter valued at approximately $29,000. Finally, Atle Fund Management AB increased its position in Bicara Therapeutics by 23.0% during the 2nd quarter. Atle Fund Management AB now owns 147,380 shares of the company's stock valued at $1,369,000 after buying an additional 27,547 shares in the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on BCAX shares. HC Wainwright dropped their target price on Bicara Therapeutics from $41.00 to $40.00 and set a "buy" rating for the company in a report on Friday, August 22nd. Piper Sandler started coverage on Bicara Therapeutics in a research report on Monday, August 18th. They set an "overweight" rating and a $36.00 price target for the company. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Bicara Therapeutics in a research report on Saturday, September 27th. Finally, Wedbush reaffirmed an "outperform" rating and set a $30.00 price target on shares of Bicara Therapeutics in a research report on Tuesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $31.86.

Get Our Latest Report on BCAX

Bicara Therapeutics Company Profile

(Get Free Report)

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Bicara Therapeutics Right Now?

Before you consider Bicara Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.

While Bicara Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.